Price
No data yet.
Social Signal Score
Revenue
$1.63M+408.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alex Duggan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.00
- Country
- GB
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -29.44
Financials
Revenue
$1.63M+408.6%Net Income
$-1.19MEBITDA
$-1.25MFree Cash Flow
$-2.17MEPS (diluted)
$-0.00Shares Outstanding (diluted)
581.33M+650.1%Operating Expenses
$2.88MCash & Debt
$1.24MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.70M | $-9.07M | $-0.03 |
| 2024 | $13.93M | $1.29M | $0.00 |
| 2023 | $3.10M | $-6.51M | $-0.02 |
| 2022 | $0.00 | $-5.85M | $-0.02 |
| 2021 | $0.00 | $-4.96M | $-0.02 |
| 2020 | $0.00 | $-2.41M | $-0.01 |
| 2019 | $31.8K | $-8.92M | $-0.04 |
| 2018 | $0.00 | $-5.88M | $-0.04 |
| 2017 | $362.7K | $-3.90M | $-0.03 |
| 2016 | $170.4K | $-3.70M | $-0.04 |
| 2015 | $29.5K | $-5.08M | $-0.05 |
| 2014 | $43.9K | $-3.00M | $-0.03 |
| 2013 | $370.9K | $-2.21M | $-0.03 |
| 2012 | $75.0K | $-2.18M | $-0.03 |
Valuation
FAMDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
115+15.00%Social Signal Score
Mentions (2)
- Newsproactiveinvestors.co.uk·5h ago·Positive
Futura Medical launches formal sale process alongside £1.6m placing Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets. The move comes alongside a placing and subscription to raise approximately £1.6 million, which should fund it through to the conclusion of negotiations.
View source ↗ - Newsproactiveinvestors.co.uk·2d ago·Neutral
Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market Performance Group as its new US commercial partner from 1 September, replacing Haleon after a two-month transition.
View source ↗
Earnings
Tue, Sep 22(in 3 weeks)
Estimates and results for FAMDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.